Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Lumacaftor-ivacaftor on Glucose Handling and Tolerance in Cystic Fibrosis Phe508del (LIGHT-CF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02653027
Recruitment Status : Withdrawn (Potential subjects were already on the combination therapy.)
First Posted : January 12, 2016
Last Update Posted : July 31, 2019
Sponsor:
Information provided by (Responsible Party):
Jose C. Florez, MD, PhD, Massachusetts General Hospital

Brief Summary:
The purpose of this research study is to find out if the combined therapy lumacaftor-ivacaftor effects how people with cystic fibrosis respond to an oral glucose tolerance test, a test for diabetes.

Condition or disease Intervention/treatment Phase
Diabetes Cystic Fibrosis Drug: Lumacaftor-ivacaftor Other: OGTT Not Applicable

Detailed Description:

This is a single center, open label study with crossover in patients with Cystic Fibrosis (CF). Patients will have 2-3 visits at the Diabetes Center at Massachusetts General Hospital (MGH).

The participants will have been previously screened clinically to make sure they are candidates for starting the combination drug, lumacaftor-ivacaftor. These patients will be contacted prior to their first visit to discuss enrollment in the study.

At the first study visit (Visit 1), the participant will come to the Diabetes Center after an overnight fast of at least 8 hours. The following will occur at this study visit: informed consent; brief medical history; weight and height; vital signs and blood pressure; blood draw for DNA extraction, and an extra research tube for storage; administration of 75g Glucola load as per a standard oral glucose tolerance test (OGTT) protocol; and blood work for glucose and insulin at 30, 60, 90 and 120 minutes after the glucose load. This will be scheduled at a time that is convenient to the patient, with an attempt to coordinate with the patient's visit to the CF clinic prior to starting lumacaftor-ivacaftor combination drug.

At the 2nd study visit (Visit 2), which will take place 3 months after starting the combination drug, the participant will again come to the Diabetes Center after an overnight fast of at least 8 hours. The participant will undergo a second OGTT as in the first visit. The 3rd study visit (Visit 3) will be 6 months after initiation of the drug, and will have a repeat administration of an OGTT. If a participant starts the combination drug before enrolling in the study, he/she can still participate in the study as long as he or she has had a clinical OGTT performed within 6 months of starting the combination drug. In these cases, the informed consent, brief medical history, weight and height and vital signs and blood pressure, as well as blood draw for DNA will occur on the Visit 2, which will be the first study visit for these participants. If a clinical OGTT had been performed prior to but within 6 months of starting the combination therapy, this OGTT can be used in analysis of the data, although will not have the full amount of data as the study OGTT.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: A Study of the Effect of Combination Lumacaftor and Ivacaftor on Glucose Tolerance in Persons With Cystic Fibrosis Who Are Homozygous for the Phe508del Cystic Fibrosis Transmembrane Conductance Regulator Mutation.
Actual Study Start Date : January 1, 2018
Estimated Primary Completion Date : February 1, 2018
Actual Study Completion Date : May 1, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis

Arm Intervention/treatment
Experimental: Lumacaftor Ivacaftor
Subjects will get an OGTT before and after starting the combination therapy lumacaftor-ivacaftor.
Drug: Lumacaftor-ivacaftor
Subjects who are planning on starting the combination therapy (lumacaftor-ivacaftor) will participate in OGTTs before and after starting the medication.
Other Name: Orkambi

Other: OGTT
A subject is given an oral glucose load and insulin and glucose measurements are taken at specified time periods.
Other Name: Oral Glucose tolerance test




Primary Outcome Measures :
  1. Change in Fasting Glucose [ Time Frame: 3 months ]
    This will be compared from baseline to 3 months after starting the medication

  2. Change in Fasting Glucose [ Time Frame: 6 months ]
    This will compare baseline to 6 months after starting the medication


Secondary Outcome Measures :
  1. Genetic risk score [ Time Frame: 6 months ]
    We will examine how the OGTT data is dependent on genotype at variants associated with type 2 diabetes using a genetic risk score

  2. Pulmonary function test (PFT) FEV1 measurements [ Time Frame: 6 months ]
    We will compare how PFT measurement of FEV1 are related to changes in OGTT

  3. Change in Fasting Insulin [ Time Frame: 3 months ]
    This will be compared from baseline to 3 months after starting the medication

  4. Change in Fasting Insulin [ Time Frame: 6 months ]
    This will be compared from baseline to 6 months after starting the medication



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18 years old or greater
  2. Patients diagnosed with CF, genotype homozygous PheDel508
  3. Subject is planning on starting lumacaftor-ivacaftor for clinical reasons, with no contraindication for starting the drug* OR subject is taking combination drug and had an OGTT done at a partners facility in the 6 months prior to initiating the drug.

    • Contraindications for taking drug include abnormal liver enzyme tests, renal dysfunction, pregnancy or nursing mothers

Exclusion Criteria:

  1. Currently taking any medications for diabetes (including oral or injectable antihyperglycemic agents and/or insulin).
  2. Had an admission for CF exacerbation less than 2 weeks prior to staring the medication. This will be defined as requiring new IV or PO antibiotics different than those used in maintenance therapy.
  3. Is currently taking oral glucocorticoids or has been on oral or IV glucocorticoids in the past 2 weeks.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02653027


Sponsors and Collaborators
Massachusetts General Hospital
Investigators
Layout table for investigator information
Principal Investigator: Jose Florez, MD, PhD Massachusetts General Hospital

Publications:
Layout table for additonal information
Responsible Party: Jose C. Florez, MD, PhD, Chief of the Diabetes Unit, Associate Professor Harvard Medical School, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT02653027     History of Changes
Other Study ID Numbers: 2015P001811
First Posted: January 12, 2016    Key Record Dates
Last Update Posted: July 31, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jose C. Florez, MD, PhD, Massachusetts General Hospital:
Genetics
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Ivacaftor
Chloride Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action